CADTH health technology review
A customized review of a health technology that may consist of one, or a combination of, the following: an environmental scan, a rapid review, a clinical review, a pharmacoeconomic review, and patient perspectives, as well as legal, ethical, social, implementation, environmental, and policy implicat...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
[2021]-, 2021
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| LEADER | 01554nas a2200229 u 4500 | ||
|---|---|---|---|
| 001 | EB002202506 | ||
| 003 | EBX01000000000000001339709 | ||
| 005 | 00000000000000.0 | ||
| 007 | tu||||||||||||||||||||| | ||
| 008 | 240412 p r ||| eng | ||
| 245 | 0 | 0 | |a CADTH health technology review |h Elektronische Ressource |
| 260 | |a Ottawa (ON) |b Canadian Agency for Drugs and Technologies in Health |c [2021]-, 2021 | ||
| 300 | |a 1 online resource | ||
| 533 | |n (reproduction note) | ||
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health | |
| 041 | 0 | 7 | |a eng |2 ISO 639-2 |
| 989 | |b NCBI |a National Center for Biotechnology Information | ||
| 362 | 0 | |a Began with January 2021 | |
| 247 | 0 | 0 | |a CADTH health technology assessment |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK571348 |3 Volltext |
| 082 | 0 | |a 600 | |
| 520 | |a A customized review of a health technology that may consist of one, or a combination of, the following: an environmental scan, a rapid review, a clinical review, a pharmacoeconomic review, and patient perspectives, as well as legal, ethical, social, implementation, environmental, and policy implications of health technologies. Appropriate use recommendations are provided where applicable. Health Technology Reviews are published in CADTH's Canadian Journal of Health Technologies, an open-access, scientific and policy journal. Topics covered are relevant to health policy decision-makers, clinicians, patients, caregivers, the pharmaceutical and medical device industry, and the Canadian and global health technology assessment community | ||